Assenagon Asset Management S.A. Has $179.87 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Assenagon Asset Management S.A. increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 265.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 435,049 shares of the company's stock after acquiring an additional 316,048 shares during the period. Assenagon Asset Management S.A. owned 0.53% of IDEXX Laboratories worth $179,867,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in IDXX. Chicago Partners Investment Group LLC lifted its stake in shares of IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after buying an additional 96 shares during the last quarter. National Pension Service lifted its position in IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after acquiring an additional 12,647 shares during the last quarter. Insight Wealth Strategies LLC boosted its holdings in IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after acquiring an additional 7,041 shares during the period. Larson Financial Group LLC grew its position in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after purchasing an additional 2,241 shares during the last quarter. Finally, Quest Partners LLC grew its position in shares of IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company's stock valued at $1,450,000 after purchasing an additional 2,801 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.11% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Piper Sandler restated a "neutral" rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $539.63.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded up $4.29 during midday trading on Wednesday, reaching $422.92. 587,272 shares of the company's stock were exchanged, compared to its average volume of 546,552. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The company's 50 day simple moving average is $423.98 and its two-hundred day simple moving average is $458.99. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The firm has a market capitalization of $34.63 billion, a PE ratio of 40.78, a price-to-earnings-growth ratio of 3.94 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories's quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.53 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.